Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCC-SIGHT: Platform Trial for Advanced Hepatocellular Carcinoma
NCT07328009Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, QL1706, camrelizumab, tauroursodeoxycholic acid in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Jan 2026; status: recruiting.
02
Drugs
tislelizumabQL1706camrelizumabtauroursodeoxycholic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07328009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328009.